The graphic provides an overview of PrEP products currently available and in late-stage clinical trials.
HIV Prevention Product Overview
People’s Research Agenda 2025 Update Summary Table
The People’s Research Agenda sets out a people-centered framework for equitable and accelerated R&D and product introduction. It tracks the science, shows where investments align—or fail to align—with community-defined priorities, and spotlights critical gaps in the pipeline of prevention options needed to meet the diverse realities of all populations. View this summary table or see the full report and dashboard.
Cabotegravir Regulatory Approval
Regulatory approvals and those pending for cabotegravir as of January 2026. For product approvals, volumes, implementation, and price comparisons of long-acting PrEP, visit our dashboard on PrEPWatch.org.
Multipurpose Prevention Technologies (MPTs) Studies Halted by USAID Funding Termination
This graphic shows a list of which studies have been halted by eliminated USAID funding.
At A Glance: The MPT R&D Pipeline
This graphic shows the status of products in development.
HIV Prevention Pipeline: Products to Watch
From the People’s Research Agenda, this graphic tracks the pipeline of potential new HIV prevention options across broadly neutralizing antibodies, preventive vaccines, pre-exposure prophylaxis, and multipurpose technologies.
Spotlight on MPTs Addressing STIs
This graphic outlines the development journey of multipurpose technologies (MPTs) that guard against STIs, including HIV, while also preventing pregnancy. It tracks the advancement of various potential products through different trial stages, emphasizing their combined protective roles.
PrEP Price Comparison
Comparing the annual price of oral TDF/FTC vs. the dapivirine vaginal ring and injectable cabotegravir. For product approvals, volumes, implementation, and price comparisons of long-acting PrEP, visit our dashboard on PrEPWatch.org.
HIV-Specific Neutralizing Antibodies by Target
A number of broadly neutralizing antibodies that target various regions of HIV’s Env protein are being developed for HIV prevention.
Broadly Neutralizing Antibody Combinations
Overview of the combinations of broadly neutralizing antibodies (bNAbs) under investigation in early clinical studies for HIV prevention.